Although we could not find studies specifically addressing the p53-dependent antitumor activity of a combination therapy involving a Topo II inhibitor and a DNA-PK inhibitor in solid tumor models, our hypothesis is supported by research conducted on acute myeloid leukemia (AML) cells. The gene discussed is TP53; the disease is acute myeloid leukemia.